Abstract

Neuroleptic malignant syndrome (NMS) is a rare but potentially lethal neurologic disorder caused by an adverse drug reaction from association with neuroleptic antipsychotic medications or other medications that interact with dopamine. It is characterized by muscle rigidity, pyrexia, increased muscle enzymes, and altered mental status. Critical complications such as acute liver, renal, and respiratory failure are significant risk factors that can lead to death. Diagnosing the syndrome early may present a challenge, because some clinical indicators may be absent or delayed. Acute management of symptoms can encompass a combination of pharmacologic interventions, which involve a multidisciplinary collaboration of health care providers. Nurse practitioners may encounter this uncommon situation; therefore, it is vital to reevaluate steps in caring for a client whose presentation is NMS.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.